WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > ACI Limited
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pharma Tech
Astellas Pharma Inc. | September 30, 2022
Astellas Pharma Inc. announced the European Medicines Agency has accepted for regulatory review the company's marketing authorization application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2 "More than half of women 40 to 64 years of age ex...
Business-standard | April 23, 2020
Concerns over price erosion in the US market, which has impacted the revenue growth of Indian pharma majors over the last four years, could be reversing. The drug shortages in the US market have increased by 37 per cent since December 2017. Kunal Randeria of Antique Stock Broking says drug shortages are at five-year highs and there is a direct correlation between drug shortage and prices. This is evident as price erosion peaked in 2017 when shortages were at their lowest levels. Concerns over pr...
Pharmacy Market
PRNewswire | August 17, 2023
Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. In addition, it provides consulting services, especially in quality control and assurance as well as in Natu...
Iktos and Chiesi Group | December 03, 2021
ktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the international research-focused pharmaceutical and healthcare. Under the agreement, Iktos’s de novo generative design software Makya™ will be used by Chiesi scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Chiesi’s drug discovery p...
Article
PHARMACY MARKET
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE